(Q37039824)

17 August 2017

Evaluation of biological agents targeted at early-stage disease (English)

1 reference

17 August 2017

Marta Guix

1

1 reference

17 August 2017

Ingrid A Mayer

series ordinal

2

1 reference

17 August 2017

Ingrid M Meszoely

series ordinal

3

1 reference

17 August 2017

Carlos L Arteaga

series ordinal

4

1 reference

17 August 2017

18 December 2008

1 reference

17 August 2017

Breast Cancer Research

1 reference

17 August 2017

10 Suppl 4

1 reference

17 August 2017

S25

1 reference

Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer

17 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2614851

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2614851

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2614851

Identification of a basal-like subtype of breast ductal carcinoma in situ

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2614851

Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2614851

Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2614851

Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2614851

Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2614851

Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2614851

Antiproliferative effects of idoxifene in a placebo-controlled trial in primary human breast cancer.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2614851

Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2FBCR2185

Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19128439

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Phosphorylation of ERα at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERα phosphorylation in breast cancer progression

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19128439

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19128439

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/BCR2185

1 reference

Dimensions Publication ID

17 August 2017

0 references

1 reference

17 August 2017

PubMed publication ID

19128439

1 reference